Amedisys, Inc. (NASDAQ:AMED) Given Average Rating of “Hold” by Analysts

Shares of Amedisys, Inc. (NASDAQ:AMED) have received a consensus rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $100.75.

Separately, Stephens restated an “equal weight” rating and set a $101.00 price target on shares of Amedisys in a research report on Wednesday, February 12th.

Institutional Investors Weigh In On Amedisys

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMED. National Bank of Canada FI raised its position in shares of Amedisys by 119.0% in the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock valued at $5,365,000 after purchasing an additional 30,213 shares during the period. Geode Capital Management LLC grew its stake in Amedisys by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock valued at $54,746,000 after buying an additional 7,071 shares in the last quarter. ABC Arbitrage SA purchased a new stake in shares of Amedisys during the fourth quarter worth $2,522,000. Quarry LP bought a new position in shares of Amedisys in the third quarter worth $2,569,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Amedisys by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock valued at $33,400,000 after purchasing an additional 9,004 shares in the last quarter. 94.36% of the stock is currently owned by institutional investors.

Amedisys Stock Performance

Shares of AMED opened at $92.55 on Wednesday. The stock has a 50 day moving average of $90.39 and a 200 day moving average of $93.50. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of 36.73, a PEG ratio of 1.82 and a beta of 0.73. Amedisys has a 12 month low of $82.15 and a 12 month high of $98.95. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.